drugset / Trial / NCT04834375

Randomized Open Investigation Determining Steroid Dose

NCT04834375 ↗

Phase 3 Completed 142 enrolled Northwell Health
RandomizedParallel-groupOpen-labelTreatment

Summary

Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.

Timeline

Start
2021-03-19
Primary completion
2022-01-25
Completion
2022-03-29

Outcome

Missed primary endpoint

paper There was no statistically significant difference in the primary outcome of 28-day all-cause mortality PMID 36475114 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.2 mg/kg Intravenous

Indications